Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy

• Published in: Targeted oncology 2022-05, Vol.17 (3), p.343-353
• Main Authors: Mizukami, Takuro, Takahashi, Masaki, Sunakawa, Yu, Yuki, Satoshi, Kagawa, Yoshinori, Takashima, Atsuo, Kato, Kyoko, Hara, Hiroki, Denda, Tadamichi, Yamamoto, Yoshiyuki, Shiozawa, Manabu, Oki, Eiji, Okamoto, Wataru, Yoshino, Takayuki, Eguchi Nakajima, Takako
• Format: Article
• Language: English
• Subjects: Biomedicine; Chemotherapy; Clinical medicine; Clinical outcomes; Colorectal cancer; Epidermal growth factor; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Monoclonal antibodies; Oncology; Original Research Article; Standard of care; Tumors
• ISSN: 1776-2596; 1776-260X
• DOI: 10.1007/s11523-022-00880-3

Background Primary tumor site and genomic status are utilized for regimen selection in metastatic colorectal cancer; however, the impact on clinical practice is not well known. Objective We aimed to clarify the impact of primary tumor site and genomic status on clinical practice in metastatic colorectal cancer. Methods The relationship between primary tumor site, genomic alterations, and clinical outcomes was evaluated in patients with untreated metastatic colorectal cancer using real-world data of a prospective observational study, SCRUM-Japan GI-SCREEN with clinical and genomic data set in 1011 patients enrolled from February 2015 to March 2017. Results Five hundred and sixty-one patients were eligible for this study. Patients with right-sided tumors had a significantly worse survival, left-sided tumors with wild-type RAS had favorable outcomes when treated with anti-epidermal growth factor receptor monoclonal antibodies, and cecum tumors had poor prognosis when treated with bevacizumab. The rate of gene alterations varied considerably depending on the primary site. In addition, gene alterations of KRAS , BRAF , SMAD4 , or TP53 had individually different contributions to survival from site to site. KRAS , BRAF , PTEN , or SMAD4 mutations were associated with efficacy of bevacizumab or anti-epidermal growth factor receptor monoclonal antibodies. Conclusions Primary tumor site is a clinically useful biomarker to predict survival in patients with metastatic colorectal cancer treated with first-line chemotherapy. Moreover, the prognostic or predictive value of several gene alterations by primary tumor site should be considered in clinical practice.